2,6-Quinolinyl Derivatives for Selective Integrin Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases and conditions mediated by integrins α4β1 and α4β7 lack effective and selective inhibitors with improved oral bioavailability and minimal impact on other integrin subgroups, leading to suboptimal therapeutic outcomes.
Innovation Solution
Development of 2,6-quinolinyl derivatives with specific structural modifications, such as methyl-(2S)-2-[(3,5-dichloroisonicotinoyl)amino]-3-[2-(2,6-dichlorophenyl)-6-quinolinyl]propanoate, which act as potent and selective inhibitors of α4 integrins, offering enhanced oral bioavailability and reduced clearance, while minimizing action on other integrin subgroups.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional integrin inhibitors are used, then inflammatory diseases can be treated, but oral bioavailability is poor and clearance is high
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of quinolinyl derivatives, specifically varying substituents at positions 2 and 6 of the quinoline ring, as well as modifications to the R1, R2, R3 groups and n values. These structural parameter changes optimize the compounds for improved oral bioavailability and reduced clearance while maintaining integrin inhibitory activity, directly resolving the contradiction between therapeutic efficacy and pharmacokinetic properties.
2Adaptability or versatility
If broad-spectrum integrin inhibitors are used, then multiple inflammatory conditions can be treated, but selectivity among integrin subgroups is lost
Solution Approach 1:
The patent applies local quality by designing compounds with specific local structural features at key positions of the quinolinyl core. The substituents at positions 2 and 6, along with specific configurations of R1, R2, R3 groups, create localized interactions that confer selectivity for α4β1 and α4β7 integrins over other integrin subgroups. This allows the compounds to maintain broad treatment coverage for various inflammatory conditions while achieving precise selectivity at the molecular level.
3Power
If potent integrin inhibitors are developed, then pharmacological effects are enhanced, but impact on other integrin subgroups increases
Solution Approach 1:
The patent applies the intermediary principle by using the quinolinyl derivative structure as a selective mediator that specifically binds to α4β1 and α4β7 integrins. The carefully designed substituents and stereochemistry (such as the (2S) configuration) act as intermediaries that facilitate selective interaction with the target integrins while sterically or chemically preventing binding to other integrin subgroups, thus enhancing pharmacological effects without increasing off-target inhibition.
Data Source
AI summary
The present invention concerns 2.6-quinolinyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceu ticals. For example, the compounds according to the invention are useful for the treatment of asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoi arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, and atherosclerosis.